Chapter 3: XEVPRM technical specifications, user guidance and practical examples of the Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA

Chapter 3: XEVPRM technical specifications, user guidance and practical examples of the Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA:

Chapter 3 of this comprehensive guide ventures into the heart of the electronic submission process for medicinal product information to the European Medicines Agency (EMA). This chapter focuses on the eXtended EudraVigilance Product Report Message (XEVPRM), the cornerstone of electronic submissions for marketing authorization holders (MAHs).

XEVPRM: The Backbone of Electronic Submissions

The XEVPRM serves as the standardized format for electronically submitting information on medicinal products for human use to the EMA. This structured data format ensures consistency and facilitates efficient data processing by the EMA.

Understanding the XEVPRM Schema

This chapter delves into the technical specifications of the XEVPRM schema, providing a roadmap for MAHs to navigate the data structure. Key elements explored include:

• Data Elements: A detailed breakdown of the specific data elements required for each medicinal product submission. This encompasses information on product characteristics, marketing authorization details, and safety reporting.
• Data Types: An explanation of the different data types used within the XEVPRM format, such as text, codes, and dates.
• Controlled Vocabularies: A breakdown of the controlled vocabularies used within the XEVPRM format. These standardized terminologies ensure consistency and accuracy of the submitted data.
• Relationships between Data Elements: An explanation of the relationships between various data elements within the XEVPRM schema. This helps MAHs understand how different pieces of information interlink.

By comprehending the XEVPRM schema, MAHs can construct accurate and compliant electronic submissions for their medicinal products.

User Guidance for Effective Submissions

This chapter goes beyond technical specifications, offering practical user guidance for MAHs to leverage the XEVPRM format effectively. Key aspects covered include:

• Data Entry Best Practices: Recommendations for accurate and efficient data entry within the XEVPRM format.
• Validation and Error Correction: Guidance on identifying and correcting potential errors during the submission process.
• Data Maintenance: Strategies for keeping product information up-to-date within the EMA’s system.

By following this user guidance, MAHs can ensure the quality and timeliness of their electronic submissions, expediting the regulatory process for their medicinal products.

Practical Examples for Clarity

To solidify understanding, this chapter provides practical examples of how to populate the XEVPRM format with real-world medicinal product information. These examples showcase the application of data elements, controlled vocabularies, and data relationships within the XEVPRM schema.

By working through these practical examples, MAHs gain hands-on experience and build confidence in constructing accurate electronic submissions for the EMA.

Conclusion of Chapter 3

Chapter 3 has equipped MAHs with a comprehensive understanding of the XEVPRM format, its technical specifications, user guidance, and practical applications. This knowledge empowers MAHs to navigate the electronic submission process efficiently and ensure the smooth regulatory assessment of their medicinal products for human use.

The next chapter will explore the data elements required for successful submissions, providing a detailed breakdown of the information needed by the EMA.

Chapter 3.I: Technical specifications of the Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA:

Chapter 3.II: XEVPRM user guidance of the Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA

Chapter 3.III: Practical examples of the Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA